A practical exam app based on the 2025 ACC concise clinical guidance on medical weight management
for optimizing cardiovascular health.
Course progress0%
Start Here
What learners will be able to do
Learner registration
Enter the learner's information before starting. Results are stored in this browser and can be exported for upload to a roster or LMS.
Frame obesity clinically
Recognize obesity as a chronic disease with direct cardiovascular implications, not a simple lifestyle failure.
Select candidates thoughtfully
Use BMI, anthropometrics, excess adiposity, weight-related consequences, contraindications, and patient goals.
Manage longitudinally
Plan dose titration, side effect monitoring, medication de-escalation, multidisciplinary support, and long-term therapy.
Source basis: This app is adapted for education from the 2025 ACC expert consensus statement on medical weight management
for optimization of cardiovascular health. It is educational only and is not a diagnostic device, prescribing tool, coverage determination,
or substitute for clinician judgment, local policy, or the full guideline.
Module 1
Obesity is a cardiovascular disease driver
The ACC document frames obesity as a chronic disease with cardiovascular implications. Obesity increases risk
through hemodynamic, inflammatory, metabolic, functional, and structural pathways.
Obesity is associated with heart failure, coronary artery disease, stroke, atrial fibrillation, sudden cardiac death, venous thromboembolism, and valvular disease.
It contributes to cardiovascular risk factors including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and physical inactivity.
Weight loss thresholds matter: about 5% can improve risk factors, while larger losses may be needed for obesity-related comorbidity and cardiovascular outcome improvement.
The cardiovascular community is encouraged to engage directly in obesity treatment because the disease is common and affects cardiovascular outcomes.
Clinical frame
Not: a willpower problem.
Yes: a chronic disease influenced by genetics, neurohormonal pathways, psychology, social determinants, medications, medical conditions, and environment.
Knowledge check
Which statement best reflects the paper's framing?
Module 2
Diagnosis and eligibility require more than a number
Measure
What it adds
Limitation
BMI
Useful population-level weight category and common eligibility anchor.
Does not fully account for adiposity, fat distribution, sex, race, or muscle mass.
Waist circumference
Identifies central adiposity and cardiometabolic risk.
Thresholds differ by population and need consistent clinical use.
Waist-to-height ratio
Can help identify central adiposity across body sizes.
Requires broader implementation and interpretation.
Clinical consequences
Links weight to impaired organ function, functional status, CVD risk, OSA, T2DM, MASLD, and HFpEF.
Requires individualized assessment.
The document notes that BMI thresholds can differ by ancestry. For example, lower BMI cut points may be appropriate for South Asian and Chinese populations because health risk can occur at lower BMI values.
MeasureBMI plus adiposity markers
StageOrgan and functional consequences
ScreenContraindications and pregnancy plans
PlanGoals, access, side effects, follow-up
Module 3
NuSH therapies and medication choice
What NuSH means
Nutrient-stimulated hormone therapies act on metabolic and appetite pathways. In this guidance, the category includes GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.
Preferred options
Semaglutide and tirzepatide are described as the obesity medications of choice among current NuSH therapies because of higher efficacy and outcome evidence.
Practical selection
Insurance coverage, availability, affordability, adverse effects, contraindications, and patient preference often determine which agent can actually be used.
LiraglutideDaily GLP-1 receptor agonist with lower average weight loss than newer weekly agents.
SemaglutideWeekly GLP-1 receptor agonist with strong weight loss and cardiovascular outcome evidence.
TirzepatideWeekly dual GLP-1/GIP agonist with high average weight loss; cardiovascular outcome data continue to evolve.
Knowledge check
Which statement best describes NuSH therapies?
Module 4
Comorbidities, side effects, and monitoring
Monitor common effects
GI symptoms such as nausea, diarrhea, vomiting, abdominal pain, and constipation are common. Dose reduction, slower titration, hydration, and behavioral strategies may help.
Adjust related therapies
As weight and cardiometabolic status improve, antihypertensives, diuretics, diabetes medications, CPAP settings, thyroid dosing, anticoagulants, or other weight-based medications may need reassessment.
Avoid unsafe shortcuts
The document discourages compounded NuSH therapies because of dosing error and counterfeit or impurity concerns.
GI side effectsSlow or reduce dose
Low BP or volume lossReassess antihypertensives or diuretics
Diabetes medsReduce hypoglycemia risk
Pregnancy planningStop weekly agents in advance
Long-term obesity treatment is usually the default plan. Stopping medication commonly leads to weight regain unless the patient and clinician decide otherwise.
Module 5
Patient-centered, team-based obesity care
The guidance emphasizes that obesity care should be respectful, longitudinal, multidisciplinary, and realistic about access.
Patients need evidence-based treatment, not blame.
Use person-first language and design spaces with appropriate chairs, gowns, scales, cuffs, exam tables, and imaging/procedure capacity.
Initial visits should identify contributors, consequences, contraindications, anthropometrics, goals, and treatment preferences.
More frequent contact can improve weight loss and maintenance, especially during titration and early follow-up.
Team members may include clinicians, pharmacists, registered dietitians, behavioral therapists, and exercise physiologists.
Access barriers are real; cost and coverage influence medication choice and can push patients toward unsafe unregulated options.
Care goal
Not just a scale number. Goals can include cardiometabolic risk reduction, quality of life, functional status, sleep apnea improvement, HFpEF symptom improvement, and psychosocial health.
StartDiagnose, stage, and set goals
TitrateMonitor response and side effects
AssessLook for at least 5% weight loss early
MaintainContinue therapy and lifestyle supports
CoordinateAdjust comorbidity treatments
Summary
High-yield takeaways
Use this screen for a fast review before visuals, flashcards, and the exam.
Key point
Obesity is framed as a chronic disease with direct cardiovascular consequences, not a willpower failure.
Key point
BMI is useful but incomplete; waist measures, adiposity, ancestry, comorbidities, and function matter.
Key point
NuSH therapies include GLP-1 and GLP-1/GIP pathway treatments, with semaglutide and tirzepatide emphasized for efficacy.
Key point
Monitoring includes GI effects, hydration, kidney risk, pregnancy planning, and medication de-escalation as weight and risk factors improve.
Key point
Long-term treatment is usually needed because stopping therapy commonly leads to regain.
Key point
Patient-centered care requires respectful language, appropriate equipment, team support, access planning, and realistic goals.
Infographics
Visual teaching summaries
Use these on screen before flashcards and the exam. Printing is optional.
Medical weight management pathway
Treat obesity to improve cardiovascular health
How to read this module
Start with the clinical problem, identify key risk markers, choose the safest action, and reassess over time.
1Stage disease
2Choose therapy
3Monitor effects
4Maintain support
5Reassess over time
Flashcards
Active recall
Click the card to flip between question and answer.
QuestionLoading flashcard...
Sources
Instructor-approved source material
Learners can view the approved source basis but cannot add or change source material.
Instructor-approved source
2025 ACC expert consensus statement on medical weight management for optimization of cardiovascular health.
Feedback
Report an error or point of confusion
This saves a note in the browser and prepares an email for the instructor.
Final Exam
Check understanding
Passing score is 80%. A printable credential appears after a passing attempt.